<H1>Chapter DOI: 10.1208/aapsj070361<br/>Cited-By Count: 32</H1><table border="1" width="30%"><tr><td>Total References</td><td>131</td></tr><tr><td>Springer references</td><td>14</td></tr><tr><td>Non Springer references</td><td>117</td></tr><tr><td>BibStructured Count</td><td width="10%">130</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>105</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>4</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>3</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>4</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>4</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Cami J, Ferre M. Drug addiction.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2003;349:975&#8211;986.</td><td><a href=http://dx.doi.org/10.1056/NEJMra023160>10.1056/NEJMra023160</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Nestler EJ. Molecular basis of long-term plasticity underlying addiction.<Emphasis Type="Italic">Nat Rev Neurosci</Emphasis>. 2001;2:119&#8211;128.</td><td><a href=http://dx.doi.org/10.1038/35053570>10.1038/35053570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Mitscher LA, Baker W. Tuberculosis: a search for novel therapy starting with natural products.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 1998;18:363&#8211;374.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1098-1128(199811)18:6&lt;363::AID-MED1&gt;3.0.CO;2-I>10.1002/(SICI)1098-1128(199811)18:6&lt;363::AID-MED1&gt;3.0.CO;2-I</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibBook</td><td>McCoy CB, Inciardi JA.<Emphasis Type="Italic">Sex, Drugs, and the Continuing, Spread of AIDS</Emphasis>. Los Angeles: Roxbury Publishing Co; 1995.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibBook</td><td>National Drug Intelligence Center.<Emphasis Type="Italic">National Drug Threat Assessment 2004</Emphasis>. Washington, DC: US Department of Justice; 2004.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Howell LL, Wilcox KM. The dopamine transporter and cocaine medication development: drug self-administration, in nonhuman primates.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;298:1&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibBook</td><td>National DI.<Emphasis Type="Italic">C. National Drug Threat, Assessment</Emphasis>. Johnston, PA: US Department of Justice; 2001.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem.<Emphasis Type="Italic">J Psychoactive Drugs</Emphasis>. 2000;32:137&#8211;141.</td><td><a href=http://dx.doi.org/10.1080/02791072.2000.10400221>10.1080/02791072.2000.10400221</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, Author_FamilyName_1, VolumeID, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Rawson RA, Anglin MD, Ling W. Will the methamphetamine problem go away?.<Emphasis Type="Italic">J Addict Dis</Emphasis>. 2002;21:5&#8211;19.</td><td><a href=http://dx.doi.org/10.1300/J069v21n01_02>10.1300/J069v21n01_02</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rood</span> <span style='background:#DDDDDD'>L.</span></span></aug> <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Carroll FI, Howell LL, Kuhar, MJ. Pharmacotherapies for treatment of cocaine abuse preclinical aspects.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1999;42:2721&#8211;2736.</td><td><a href=http://dx.doi.org/10.1021/jm9706729>10.1021/jm9706729</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine.<Emphasis Type="Italic">Trends Neurosci</Emphasis>. 1991;14:299&#8211;302.</td><td><a href=http://dx.doi.org/10.1016/0166-2236(91)90141-G>10.1016/0166-2236(91)90141-G</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence.<Emphasis Type="Italic">Science</Emphasis>. 1988;242:715&#8211;723.</td><td><a href=http://dx.doi.org/10.1126/science.2903550>10.1126/science.2903550</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction.<Emphasis Type="Italic">Brain Res Brain Res Rev</Emphasis>. 1993;18:247&#8211;291.</td><td><a href=http://dx.doi.org/10.1016/0165-0173(93)90013-P>10.1016/0165-0173(93)90013-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal.<Emphasis Type="Italic">Trends Pharmacol Sci</Emphasis>. 1996;17:260&#8211;264.</td><td><a href=http://dx.doi.org/10.1016/0165-6147(96)10024-9>10.1016/0165-6147(96)10024-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor, agonists.<Emphasis Type="Italic">Neuropharmacology</Emphasis>. 1997;36:373&#8211;381.</td><td><a href=http://dx.doi.org/10.1016/S0028-3908(97)00010-5>10.1016/S0028-3908(97)00010-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1995;274:1414&#8211;1424.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibArticle</td><td>McMahon LR, Cunningham KA. Antagonism of 5-Hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;297:357&#8211;363.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Kelley AE, Lang CG. Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1989;167:385&#8211;395.</td><td><a href=http://dx.doi.org/10.1016/0014-2999(89)90447-0>10.1016/0014-2999(89)90447-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Carroll FI, Kotian P, Dehghani A, et al. Cocaine and 3&#946;-(4&#8242;-Substituted phenyl)tropane-2&#946;-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1995;38:379&#8211;388.</td><td><a href=http://dx.doi.org/10.1021/jm00002a020>10.1021/jm00002a020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Belej T, Manji D, Sioutis S, Barros HM, Nobrega JN. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs post-withdrawal effects.<Emphasis Type="Italic">Brain Res</Emphasis>. 1996;736:287&#8211;296.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(96)00713-5>10.1016/0006-8993(96)00713-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Sora I, Hall FS, Andrews AM, et al. MOlecular mechanisms of cocaine reward. Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2001;98:5300&#8211;5305.</td><td><a href=http://dx.doi.org/10.1073/pnas.091039298>10.1073/pnas.091039298</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Baumann MH, Rothman RB. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans.<Emphasis Type="Italic">Biol Psychiatry</Emphasis>. 1998;44:578&#8211;591.</td><td><a href=http://dx.doi.org/10.1016/S0006-3223(98)00123-1>10.1016/S0006-3223(98)00123-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.<Emphasis Type="Italic">Synapse</Emphasis>. 2001;39:32&#8211;41.</td><td><a href=http://dx.doi.org/10.1002/1098-2396(20010101)39:1&lt;32::AID-SYN5&gt;3.0.CO;2-3>10.1002/1098-2396(20010101)39:1&lt;32::AID-SYN5&gt;3.0.CO;2-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Kulkarni SS, Newman AH, Houlihan WJ. Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2002;45:4119&#8211;4127.</td><td><a href=http://dx.doi.org/10.1021/jm0102093>10.1021/jm0102093</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions.<Emphasis Type="Italic">Nat Rev Drug Discov</Emphasis>. 2002;1:710&#8211;726.</td><td><a href=http://dx.doi.org/10.1038/nrd897>10.1038/nrd897</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Prisinzano T, Rice KC, Baumann MH, Rothman RB. Development of neurochemical normalization (&#8220;agonist substitution&#8221;) therapeutics for stimulant, abuse: focus on the dopamine uptake inhibitor, GBR 12909.<Emphasis Type="Italic">Curr Med Chem CNS Agents</Emphasis>. 2004;4:47&#8211;59.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.<Emphasis Type="Italic">Addict Behav</Emphasis>. 2004;29:1439&#8211;1464.</td><td><a href=http://dx.doi.org/10.1016/j.addbeh.2004.06.018>10.1016/j.addbeh.2004.06.018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Mello NK, Negus SS. Interactions between kappa opioid, agonists and cocaine. Preclinical studies.<Emphasis Type="Italic">Ann N Y Acad Sci</Emphasis>. 2000;909:104&#8211;132.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2000.tb06678.x>10.1111/j.1749-6632.2000.tb06678.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2001;937:50&#8211;73.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2001.tb03558.x>10.1111/j.1749-6632.2001.tb03558.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Collins SL, Kunko PM, Ladenheim B, et al. Chronic cocaine increases kappa-opioid receptor density: lack of effect by selective dopamine uptake inhibitors.<Emphasis Type="Italic">Synapse</Emphasis>. 2002;45:153&#8211;158.</td><td><a href=http://dx.doi.org/10.1002/syn.10091>10.1002/syn.10091</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Tzaferis JA, McGinty JF. Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum.<Emphasis Type="Italic">Brain Res Mol Brain Res</Emphasis>. 2001;93:27&#8211;35.</td><td><a href=http://dx.doi.org/10.1016/S0169-328X(01)00178-4>10.1016/S0169-328X(01)00178-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response.<Emphasis Type="Italic">Drug Alcohol Depend.</Emphasis> 2001;62:111&#8211;123.</td><td><a href=http://dx.doi.org/10.1016/S0376-8716(00)00181-2>10.1016/S0376-8716(00)00181-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Chao CC, Gekker G, Hu S, et al. Kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.<Emphasis Type="Italic">Proc, Natl Acad Sci USA</Emphasis>. 1996;93:8051&#8211;8056.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.15.8051>10.1073/pnas.93.15.8051</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Peterson PK, Gekker G, Lokensgard JR, et al. Kappa opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2001;61: 1145&#8211;1151.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(01)00574-3>10.1016/S0006-2952(01)00574-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Gekker G., Hu S, Wentland MP, et al. &#954;-Opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;309:600&#8211;606.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.060160>10.1124/jpet.103.060160</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Werling L, Frattali A, Portoghese P, Takemori A, Cox B. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;246:282&#8211;286.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;244:1067&#8211;1080.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1988;85:5274&#8211;5278.</td><td><a href=http://dx.doi.org/10.1073/pnas.85.14.5274>10.1073/pnas.85.14.5274</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Spanagel R, Herz A, Shippenberg TS. The effects of opioid, peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study.<Emphasis Type="Italic">J Neurochem</Emphasis>. 1990;55:1734&#8211;1740.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.1990.tb04963.x>10.1111/j.1471-4159.1990.tb04963.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Spanagel R, Herz A, Shippenberg T. Opposing tonically active endogenous opioid, systems modulate the mesolimbic dopaminergic pathway.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1992;89:2046&#8211;2050.</td><td><a href=http://dx.doi.org/10.1073/pnas.89.6.2046>10.1073/pnas.89.6.2046</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Jackisch R, Hotz H, Hertting G. No evidence for presynaptic opioid receptors on cholinergic, but presence of kappa-receptors on dopaminergic neurons in the rabbit caudate nucleus: involvement of endogenous opioids.<Emphasis Type="Italic">Naunyn Schmiedebergs Arch Pharmacol</Emphasis>. 1993;348:234&#8211;241.</td><td><a href=http://dx.doi.org/10.1007/BF00169150>10.1007/BF00169150</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Margolis EB, Hjelmstad GO, Bonci A, Fields HL. &#954;-Opioid agonists directly inhibit midbrain dopaminergic neurons.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2003;23:9981&#8211;9986.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Suzuki T, Kishimoto Y, Ozaki S, Narita M. Mechanism of opioid dependence and interaction between opioid receptors.<Emphasis Type="Italic">Eur J Pain</Emphasis>. 2001;5:63&#8211;65.</td><td><a href=http://dx.doi.org/10.1053/eujp.2001.0282>10.1053/eujp.2001.0282</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Thompson AC Jr, Zapata A, Jr, Justice JB Jr, et al. &#954;-Opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2000;20:9333&#8211;9340.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Izenwasser S, French D, Carroll FI, Funko PM. Continuous infusion of selective dopamine uptake inhibitors or cocaine produces time-dependent changes in rat locomotor activity.<Emphasis Type="Italic">Behav Brain Res</Emphasis>. 1999;99:201&#8211;208.</td><td><a href=http://dx.doi.org/10.1016/S0166-4328(98)00104-1>10.1016/S0166-4328(98)00104-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Acri JB, Thompson AC, Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappaopioid receptor agonist U 69593.<Emphasis Type="Italic">Synapse</Emphasis>. 2001;39:343&#8211;350.</td><td><a href=http://dx.doi.org/10.1002/1098-2396(20010315)39:4&lt;343::AID-SYN1018&gt;3.0.CO;2-Q>10.1002/1098-2396(20010315)39:4&lt;343::AID-SYN1018&gt;3.0.CO;2-Q</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Heidbreder CA, Schenk S, Partridge B, Shippenberg TS. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.<Emphasis Type="Italic">Synapse</Emphasis>. 1998;30:255&#8211;262.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1098-2396(199811)30:3&lt;255::AID-SYN3&gt;3.0.CO;2-A>10.1002/(SICI)1098-2396(199811)30:3&lt;255::AID-SYN3&gt;3.0.CO;2-A</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Collins SL, Gerdes RM, D&#8217;Addario C, Izenwasser S. Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity.<Emphasis Type="Italic">Behav Pharmacol</Emphasis>. 2001;12:237&#8211;245.</td><td><a href=http://dx.doi.org/10.1097/00008877-200107000-00002>10.1097/00008877-200107000-00002</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, FirstPage, Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Collins SL, D&#8217;Addario C, Izenwasser S. Effects of &#954;-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2001;426:25&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(01)01194-3>10.1016/S0014-2999(01)01194-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;173:146&#8211;152.</td><td><a href=http://dx.doi.org/10.1007/s00213-003-1716-3>10.1007/s00213-003-1716-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the endogenous &#954; opioid agonist dynorphim A(1&#8211;17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;172:422&#8211;429.</td><td><a href=http://dx.doi.org/10.1007/s00213-003-1688-3>10.1007/s00213-003-1688-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Schenk S, Partridge B, Shippenberg TS. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2000;151:85&#8211;90.</td><td><a href=http://dx.doi.org/10.1007/s002130000476>10.1007/s002130000476</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Neumeyer JL, Gu XH, van Vliet LA, et al. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2001;11:2735&#8211;2740.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(01)00543-1>10.1016/S0960-894X(01)00543-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Zukin RS, Eghbali M, Olive D, Unterwald EM, Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa, 1 and kappa 2 opioid receptors.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1988;85:4061&#8211;4065.</td><td><a href=http://dx.doi.org/10.1073/pnas.85.11.4061>10.1073/pnas.85.11.4061</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Butelman ER, Ko MC, Sobczyk-Kojiro K, et al. kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1998;285:595&#8211;601.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Caudle RM, Finegold AA, Mannes AJ, et al. Spinal kappa<Subscript>1</Subscript> and kappa<Subscript>2</Subscript> opioid binding sites in rats, guinea pigs, monkeys and humans.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1998;9:2523&#8211;2525.</td><td><a href=http://dx.doi.org/10.1097/00001756-199808030-00018>10.1097/00001756-199808030-00018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Wollemann M, Benyhe S, Simon J. The kappa-opioid receptor: evidence for the different subtypes.<Emphasis Type="Italic">Life Sci</Emphasis>. 1993;52:599&#8211;611.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(93)90451-8>10.1016/0024-3205(93)90451-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Ni Q, Xu H, Partilla JS, et al. Selective labeling of {ieE597-1} opioid receptors in rat brain by [<Superscript>125</Superscript>I]IOXY: interaction of opioid peptides and other drugs with multiple {ieE597-2} binding sites.<Emphasis Type="Italic">Peptides</Emphasis>. 1993;14:1279&#8211;1293.</td><td><a href=http://dx.doi.org/10.1016/0196-9781(93)90188-M>10.1016/0196-9781(93)90188-M</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Rothman RB, Bykov V, Xue BG, et al. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences.<Emphasis Type="Italic">Peptides</Emphasis>. 1992;13:977&#8211;987.</td><td><a href=http://dx.doi.org/10.1016/0196-9781(92)90059-C>10.1016/0196-9781(92)90059-C</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Lahti RA, Mickelson MM, McCall JM, Von Voigtlander PF. [<Superscript>3</Superscript>H]U-69593 a highly selective ligand for the opioid kappa receptor.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1985;109:281&#8211;284.</td><td><a href=http://dx.doi.org/10.1016/0014-2999(85)90431-5>10.1016/0014-2999(85)90431-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Romer D, Buscher H, Hill RC, et al. Bremazocine: a potent, longacting opiate kappa-agonist.<Emphasis Type="Italic">Life Sci</Emphasis>. 1980;27:971&#8211;978.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(80)90107-1>10.1016/0024-3205(80)90107-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.<Emphasis Type="Italic">Life Sci</Emphasis>. 1987;40:1287&#8211;1292.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(87)90585-6>10.1016/0024-3205(87)90585-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin CE, Takemori AE. Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1991;34:1292&#8211;1296.</td><td><a href=http://dx.doi.org/10.1021/jm00108a008>10.1021/jm00108a008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Clark JA, Liu L, Price M, et al. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa1 subtypes and a novel kappa3, subtype.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1989;251:461&#8211;468.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1994;45:330&#8211;334.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;485:119&#8211;125.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.11.078>10.1016/j.ejphar.2003.11.078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1&#8211;13), an extraordinarily potent opioid peptide.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1979;76:6666&#8211;6670.</td><td><a href=http://dx.doi.org/10.1073/pnas.76.12.6666>10.1073/pnas.76.12.6666</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor.<Emphasis Type="Italic">Science</Emphasis>: 1982;215:413&#8211;415.</td><td><a href=http://dx.doi.org/10.1126/science.6120570>10.1126/science.6120570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibBook</td><td>Casy AF, Parfitt RT.<Emphasis Type="Italic">Opioid Analgesics: Chemistry and Receptors</Emphasis>. New York: Plenum Press; 1986.</td><td><a href=http://dx.doi.org/10.1007/978-1-4899-0585-7>10.1007/978-1-4899-0585-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ChapterTitle, Year, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Eguchi M. Recent advances in selective opioid receptor agonists and antagonists.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2004;24:182&#8211;212.</td><td><a href=http://dx.doi.org/10.1002/med.10059>10.1002/med.10059</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Archer S, Glick SD, Bidlack JM. Cyclazocine revisited.<Emphasis Type="Italic">Neurochem Res</Emphasis>. 1996;21:1369&#8211;1373.</td><td><a href=http://dx.doi.org/10.1007/BF02532378>10.1007/BF02532378</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Glick SD, Visker KE, Maisonneuve IM. Effects of cyclazocine on cocaine self-administration in rats.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1998;357:9&#8211;14.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(98)00548-2>10.1016/S0014-2999(98)00548-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Maisonneuve IM, Glick SD. (+/-)Cyclazocine blocks the dopamine response to nicotine.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1999;10:693&#8211;696.</td><td><a href=http://dx.doi.org/10.1097/00001756-199903170-00006>10.1097/00001756-199903170-00006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Preston KL, Umbricht A, Schroeder JR, et al. Cyclazocine: comparison to hydromorphone and interaction with cocaine.<Emphasis Type="Italic">Behav Pharmacol</Emphasis>. 2004;15:91&#8211;102.</td><td><a href=http://dx.doi.org/10.1097/00008877-200403000-00001>10.1097/00008877-200403000-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Cosgrove KP, Carroll ME. Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;301:993&#8211;1002.</td><td><a href=http://dx.doi.org/10.1124/jpet.301.3.993>10.1124/jpet.301.3.993</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Nestby P, Schoffelmeer AN, Homberg JR, et al. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;142:309&#8211;317.</td><td><a href=http://dx.doi.org/10.1007/s002130050894>10.1007/s002130050894</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Wentland MP, Lou R, Ye Y, et al. 8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2, 6-methano-3-benzazocines.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2001;11:623&#8211;626.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(01)00014-2>10.1016/S0960-894X(01)00014-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Bidlack JM, Cohen DJ, McLaughlin JP, et al. 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;302:374&#8211;380.</td><td><a href=http://dx.doi.org/10.1124/jpet.302.1.374>10.1124/jpet.302.1.374</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS. Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;506:133&#8211;141.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2004.10.051>10.1016/j.ejphar.2004.10.051</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Bowen CA, Negus SS, Zong R, et al. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2003;28:1125&#8211;1139.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Szmuszkovicz J, von Voigtlander PF. Benzeneacetamide amines: structurally novel non-m&#956; opioids.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1982;25:1125&#8211;1126.</td><td><a href=http://dx.doi.org/10.1021/jm00352a005>10.1021/jm00352a005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Szmuszkovicz J. U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990.<Emphasis Type="Italic">Prog Drug Res</Emphasis>. 1999;52:167&#8211;195.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Szmuszkovicz J. U-50,488 and the kappa receptor. Part II: 1991&#8211;1998.<Emphasis Type="Italic">Prog Drug Res</Emphasis>. 1999;53:1&#8211;51.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Maisonneuve IM, Archer S, Glick SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats.<Emphasis Type="Italic">Neurosci Lett</Emphasis>. 1994;181:57&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/0304-3940(94)90559-2>10.1016/0304-3940(94)90559-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Broadbent J, Gaspard TM, Dworkin SI. Assessment of the discriminative stimulus effects of cocaine in the rat: lack of interaction with opioids.<Emphasis Type="Italic">Pharmacol Biochem Behav</Emphasis>. 1995;51:379&#8211;385.</td><td><a href=http://dx.doi.org/10.1016/0091-3057(94)00408-B>10.1016/0091-3057(94)00408-B</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Glick SD, Maisonneuve IM, Raucci J, Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats.<Emphasis Type="Italic">Brain Res</Emphasis>. 1995;681:147&#8211;152.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(95)00306-B>10.1016/0006-8993(95)00306-B</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Kuzmin AV, Semenova S, Gerrits MA, Zvartan EE, Van Ree JM. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1997;321:265&#8211;271.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(96)00961-2>10.1016/S0014-2999(96)00961-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Kantak KM, Riberdy A, Spealman RD. Cocaine-opioid interactions in groups of rats trained to discriminate different doses of cocaine.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;147:257&#8211;265.</td><td><a href=http://dx.doi.org/10.1007/s002130051165>10.1007/s002130051165</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Negus SS, Mello NK, Portoghese PS, Lin C-E. Effects of<Emphasis Type="Italic">kappa</Emphasis> opioids on cocaine self-administration by rhesus monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1997;282:44&#8211;55.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Negus SS, Mello NK. Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys.<Emphasis Type="Italic">Exp Clin Psychopharmacol</Emphasis>. 1999;7:307&#8211;317.</td><td><a href=http://dx.doi.org/10.1037/1064-1297.7.4.307>10.1037/1064-1297.7.4.307</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Negus SS. Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;176:204&#8211;213.</td><td><a href=http://dx.doi.org/10.1007/s00213-004-1878-7>10.1007/s00213-004-1878-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Schenk S, Partridge B, Shippenberg TS. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;144:339&#8211;346.</td><td><a href=http://dx.doi.org/10.1007/s002130051016>10.1007/s002130051016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Vanderschuren LJ, Schoffelmeer AN, Wardeh G, De Vries TJ. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2000;150:35&#8211;44.</td><td><a href=http://dx.doi.org/10.1007/s002130000424>10.1007/s002130000424</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>El Daly E, Chefer V, Sandill S, Shippenberg TS. Modulation of the neurotoxic effects of methamphetamine by the selective &#954; opioid receptor agonist U69593.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2000;74:1553&#8211;1562.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2000.0741553.x>10.1046/j.1471-4159.2000.0741553.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Powell KR, Holtzman SG. Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys.<Emphasis Type="Italic">Pharmacol Biochem Behav</Emphasis>. 2000;65:43&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/S0091-3057(99)00183-5>10.1016/S0091-3057(99)00183-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Sorbera L, Castaner J, Leeson P. Nalfurafine hydrochloride. Antipruritic, analgesic, kappa opioid agonist.<Emphasis Type="Italic">Drugs of the Future</Emphasis>. 2003;28:237&#8211;242.</td><td><a href=http://dx.doi.org/10.1358/dof.2003.028.03.723584>10.1358/dof.2003.028.03.723584</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Nagase H, Hayakawa J, Kawamura K, et al. Discovery of a structurally novel opioid &#954;-agonist derived from 4,5-epoxymorphinan.<Emphasis Type="Italic">Chem Pharm Bull (Tokyo)</Emphasis>. 1998;46:366&#8211;369.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Wang Y, Tang K, Inan S, et al. Comparison of pharmacological activities of three distinet &#954;-ligands (Salvinorin A, TRK-820 and 3 FLB) on &#954; opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;312:220&#8211;230.</td><td><a href=http://dx.doi.org/10.1124/jpet.104.073668>10.1124/jpet.104.073668</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Endoh T, Tajima A, Izumimoto N, et al. TRK-820, a selective &#954;-opioid agonist, produces potent antinociception in cynomolgus monkeys.<Emphasis Type="Italic">Jpn J Pharmacol</Emphasis>. 2001;85:282&#8211;290.</td><td><a href=http://dx.doi.org/10.1254/jjp.85.282>10.1254/jjp.85.282</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Endoh T, Matsuura H, Tajima A, et al. Potent antinociceptive effects of TRK-820, a novel &#954;-opioid receptor agonist.<Emphasis Type="Italic">Life Sci</Emphasis>. 1999;65:1685&#8211;1694.</td><td><a href=http://dx.doi.org/10.1016/S0024-3205(99)00417-8>10.1016/S0024-3205(99)00417-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Endoh T, Tajima A, Suzuki T, et al. Characterization of the antinociceptive effects of TRK-820 in the rat.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;387:133&#8211;140.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(99)00815-8>10.1016/S0014-2999(99)00815-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Suzuki T, Izumimoto N, Takezawa Y, et al. Effect of repeated administration of TRK-820, a &#954;-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.<Emphasis Type="Italic">Brain Res</Emphasis>. 2004;995:167&#8211;175.</td><td><a href=http://dx.doi.org/10.1016/j.brainres.2003.09.057>10.1016/j.brainres.2003.09.057</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Mori T, Nomura M, Nagase H, Narita M, Suzuki T. Effects of a newly synthesized &#954;-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2002;161:17&#8211;22.</td><td><a href=http://dx.doi.org/10.1007/s00213-002-1028-z>10.1007/s00213-002-1028-z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Hasebe K, Kawai K, Suzuki T, et al. Possible pharmacotherapy of the opioid &#954; receptor agonist for drug dependence.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2004;1025:404&#8211;413.</td><td><a href=http://dx.doi.org/10.1196/annals.1316.050>10.1196/annals.1316.050</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Mori T, Nomura M, Yoshizawa K, et al. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats.<Emphasis Type="Italic">Life Sci</Emphasis>. 2004;75:2473&#8211;2482.</td><td><a href=http://dx.doi.org/10.1016/j.lfs.2004.05.017>10.1016/j.lfs.2004.05.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Levi MS, Borne RF. A review of chemical agents in the pharmacotherapy of addiction.<Emphasis Type="Italic">Curr Med Chem</Emphasis>. 2002;9:1807&#8211;1818.</td><td><a href=http://dx.doi.org/10.2174/0929867023368980>10.2174/0929867023368980</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Year, Author_FamilyName_2, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR108</td><td>BibArticle</td><td>Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:394&#8211;401.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2000.tb05213.x>10.1111/j.1749-6632.2000.tb05213.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR109</td><td>BibArticle</td><td>Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 1998;844:274&#8211;292.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1998.tb08242.x>10.1111/j.1749-6632.1998.tb08242.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:354&#8211;368.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2000.tb05210.x>10.1111/j.1749-6632.2000.tb05210.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;297:531&#8211;539.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Sweetnam PM, Lancaster J, Snowman A, et al. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine&#8217;s putative anti-addictive activity.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1995;118:369&#8211;376.</td><td><a href=http://dx.doi.org/10.1007/BF02245936>10.1007/BF02245936</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR113</td><td>BibArticle</td><td>He D-Y, McGough NNH, Ravindranathan A, et al. Glial cell line-derived ne&#250;rotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2005;25:619&#8211;628.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.3959-04.2005>10.1523/JNEUROSCI.3959-04.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR114</td><td>BibArticle</td><td>Leal MB, Michelin K, Souza DO, Elisabetsky E. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-aspartate receptors.<Emphasis Type="Italic">Prog Neuropsychopharmacol Biol Psychiatry</Emphasis>. 2003;27:781&#8211;785.</td><td><a href=http://dx.doi.org/10.1016/S0278-5846(03)00109-X>10.1016/S0278-5846(03)00109-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR115</td><td>BibArticle</td><td>Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine.<Emphasis Type="Italic">Ann N Y Acad Sci</Emphasis>. 1998;844:214&#8211;226.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1998.tb08237.x>10.1111/j.1749-6632.1998.tb08237.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR116</td><td>BibArticle</td><td>Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.<Emphasis Type="Italic">Brain Res</Emphasis>. 1997;749:340&#8211;343.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(96)01414-X>10.1016/S0006-8993(96)01414-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR117</td><td>BibArticle</td><td>Cappendijk SL, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1993;241:261&#8211;265.</td><td><a href=http://dx.doi.org/10.1016/0014-2999(93)90212-Z>10.1016/0014-2999(93)90212-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR118</td><td>BibArticle</td><td>Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.<Emphasis Type="Italic">Brain Res</Emphasis>. 1994;657:14&#8211;22.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(94)90948-2>10.1016/0006-8993(94)90948-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR119</td><td>BibArticle</td><td>Sershen H, Hashim A, Harsing L, Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice.<Emphasis Type="Italic">Life Sci</Emphasis>. 1992;50:1079&#8211;1086.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(92)90344-O>10.1016/0024-3205(92)90344-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR120</td><td>BibArticle</td><td>Maisonneuve IM Jr, Rossman KL, Jr, Keller RW Jr, Glick SD. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats.<Emphasis Type="Italic">Brain Res</Emphasis>. 1992;575:69&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(92)90424-8>10.1016/0006-8993(92)90424-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR121</td><td>BibArticle</td><td>Szumlinski KK, Maisonneuve IM, Glick SD. Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;398:259&#8211;262.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(00)00325-3>10.1016/S0014-2999(00)00325-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR122</td><td>BibArticle</td><td>Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine.<Emphasis Type="Italic">Am J Addict</Emphasis>. 1999;8:234&#8211;242.</td><td><a href=http://dx.doi.org/10.1080/105504999305848>10.1080/105504999305848</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR123</td><td>BibArticle</td><td>O&#8217;Hearn E, Molliver ME. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.<Emphasis Type="Italic">J Neurosci</Emphasis>. 1997;17:8828&#8211;8841.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR124</td><td>BibArticle</td><td>Bandarage UK, Kuehne ME, Glick SD. Chemical synthesis and biological evaluation of 18-methoxycoronaridine (18-MC) as a potential anti-addictive agent.<Emphasis Type="Italic">Curr Med Chem CNS Agents</Emphasis>. 2001;1:113&#8211;123.</td><td><a href=http://dx.doi.org/10.2174/1568011013354723>10.2174/1568011013354723</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR125</td><td>BibArticle</td><td>Kuehne ME, He L, Jokiel PA, et al. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2003;46:2716&#8211;2730.</td><td><a href=http://dx.doi.org/10.1021/jm020562o>10.1021/jm020562o</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR126</td><td>BibArticle</td><td>Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy., toxicity, and mechanisms of action.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:369&#8211;386.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2000.tb05211.x>10.1111/j.1749-6632.2000.tb05211.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR127</td><td>BibArticle</td><td>Glick SD, Maisonneuve IM, Dickinson HA. 18-MC reduces methamphetamine and nicotine self-administration in rats.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2000;11:2013&#8211;2015.</td><td><a href=http://dx.doi.org/10.1097/00001756-200006260-00041>10.1097/00001756-200006260-00041</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR128</td><td>BibArticle</td><td>Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener.<Emphasis Type="Italic">Alkaloids Chem Biol</Emphasis>. 2001;56:39&#8211;53.</td><td><a href=http://dx.doi.org/10.1016/S0099-9598(01)56006-X>10.1016/S0099-9598(01)56006-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR129</td><td>BibArticle</td><td>Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2002;99:11934&#8211;11939.</td><td><a href=http://dx.doi.org/10.1073/pnas.182234399>10.1073/pnas.182234399</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR130</td><td>BibArticle</td><td>Chavkin C, Sud S, Jin W, et al. Salvinorin A, an active component of the hallucinogenic sage<Emphasis Type="Italic">Salvia divinorum</Emphasis> is a highly efficacious &#954;-opioid receptor agonist: structural and functional considerations.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;308:1197&#8211;1203.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.059394>10.1124/jpet.103.059394</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR131</td><td>BibArticle</td><td>Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;172:220&#8211;224.</td><td><a href=http://dx.doi.org/10.1007/s00213-003-1638-0>10.1007/s00213-003-1638-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>